Entrada Therapeutics (TRDA) Receivables - Net (2023 - 2026)

Entrada Therapeutics' Receivables - Net history runs 4 years deep, the most recent figure standing at $787000.0 for Q1 2026.

• On a quarterly basis, Receivables - Net fell 61.5% year-over-year to $787000.0 in Q1 2026; TTM through Mar 2026 was $787000.0, a 61.5% decrease from a year earlier, with the FY2025 full-year figure at $1.2 million, down 68.02% from the prior year.
• Receivables - Net declined to $787000.0 in Q1 2026 per TRDA's latest filing, from $1.2 million in the prior quarter.
• Across five years, Receivables - Net topped out at $77.5 million in Q1 2024 and bottomed at $787000.0 in Q1 2026.
• The 4-year median for Receivables - Net is $3.7 million (2024), against an average of $9.1 million.
• Across the five-year window, Receivables - Net soared 1130.97% in 2024 and plunged 97.36% in 2025, its largest moves.
• Year by year, Receivables - Net stood at $5.9 million in 2023, then slumped by 37.39% to $3.7 million in 2024, then tumbled by 68.02% to $1.2 million in 2025, then plunged by 33.14% to $787000.0 in 2026.
• Per Business Quant, the three latest TRDA Receivables - Net figures stand at $787000.0 (Q1 2026), $1.2 million (Q4 2025), and $1.2 million (Q3 2025).